BNP/CALL/MODERNA/220/0.1/20.12.24 | Delayed Deutsche Boerse AG 08:50:37 28/05/2024 BST | ||
| 1.27 EUR | +0.79% |
|
| Current month | +563.16% | ||
| 1 month | +641.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/05/24 | 1.27 | +0.79% |
| 27/05/24 | 1.26 | 0.00% |
| 24/05/24 | 1.26 | +6.78% |
| 23/05/24 | 1.18 | +3.51% |
| 22/05/24 | 1.14 | +115.09% |
Delayed Quote Deutsche Boerse AG
Last update May 28, 2024 at 08:50 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE89C5 |
| ISIN | DE000PE89C58 |
| Date issued | 16/02/2023 |
| Strike | 220 $ |
| Maturity | 20/12/2024 (207 Days) |
| Parity | 10 : 1 |
| Emission price | 3.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.93 € |
|---|---|
| Lowest since issue | 0.085 € |
| Spread | 0.04 € |
| Spread % | 3.05% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
166.6
USD
Average target price
138.5
USD
Spread / Average Target
-16.86%
- Stock Market
- Warrants
- Warrant
